SXTP60 DEGREES PHARMACEUTICALS,...

Nasdaq 60degreespharma.com


$ 0.27 $ 0.00 (0.64 %)    

Wednesday, 26-Jun-2024 15:59:50 EDT
QQQ $ 481.65 $ 1.67 (0.35 %)
DIA $ 392.19 $ 1.40 (0.36 %)
SPY $ 546.11 $ 0.63 (0.11 %)
TLT $ 93.65 $ 0.22 (0.24 %)
GLD $ 215.04 $ 0.33 (0.15 %)
$ 0.2666
$ 0.25
$ 0.00 x 0
$ 0.00 x 0
$ 0.25 - $ 0.27
$ 0.20 - $ 8.65
107,805
na
3.24M
$ 0.97
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-15-2024 03-31-2024 10-Q
2 04-01-2024 12-31-2023 10-K
3 11-20-2023 09-30-2023 10-Q
4 08-25-2023 06-30-2023 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 60-degrees-pharmaceuticals-enrolls-first-patient-in-clinical-trial-for-tafenoquine-to-treat-babesiosis-at-tufts-medical-center

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-co...

 60-degrees-pharmaceuticals-announces-fda-orphan-drug-designation-for-tafenoquine-to-treat-acute-babesiosis

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incenti...

 hc-wainwright--co-reiterates-neutral-on-60-degrees

HC Wainwright & Co. analyst Edward White reiterates 60 Degrees (NASDAQ:SXTP) with a Neutral.

 60-degrees-pharmaceuticals-begins-enrolling-for-a-clinical-trial-of-tafenoquine-for-babesiosis-at-tufts-medical-center

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate th...

 60-degrees-q1-eps-003-up-from-113-yoy-sales-8066k-up-from-5166k-yoy

60 Degrees (NASDAQ:SXTP) reported quarterly earnings of $0.03 per share. This is a 102.65 percent increase over losses of $(1.1...

 hc-wainwright--co-reiterates-neutral-on-60-degrees

HC Wainwright & Co. analyst Edward White reiterates 60 Degrees (NASDAQ:SXTP) with a Neutral.

 60-degrees-q4-eps-044-misses-020-estimate-sales-12568k-beat-7000k-estimate

60 Degrees (NASDAQ:SXTP) reported quarterly losses of $(0.44) per share which missed the analyst consensus estimate of $(0.20) ...

 why-westport-fuel-systems-shares-are-trading-lower-by-around-10-here-are-other-stocks-moving-in-tuesdays-mid-day-session

Shares of Westport Fuel Systems Inc. (NASDAQ: WPRT) fell sharply during Tuesday’s session after posting a wider-than-expected ...

 why-stoke-therapeutics-shares-are-trading-higher-by-around-70-here-are-20-stocks-moving-premarket

Shares of Stoke Therapeutics, Inc. (NASDAQ: STOK) rose sharply in today’s pre-market trading after the company announced Phase...

 60-degrees-pharmaceuticals-announces-communication-from-the-fda-of-intention-to-respond-to-tafenoquine-babesiosis-trial-protocol-submission-in-april-2024

60 Degrees Pharmaceuticals, Inc., (NASDAQ:SXTP, SXTPW)))) ("60 Degrees Pharmaceuticals" or the "Company"), a ph...

 60-degrees-pharmaceuticals-to-sponsor-pre-clinical-studies-of-tafenoquine-use-in-candida-spp-including-candida-auris

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine's presumed mod...